# US 2008/0307536 A1 · Voltage-Gated, Ph-Sensitive Anion Channel And Its Novel Splice Variant Involved In Taste Sensation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0307536 A1
- Document ID: US20080307536A1
- Status: Published application
- Kind: A1
- Application number: 11/721,597
- Filed: 2005-12-13
- Published: 2008-12-11
- Earliest claimed: 2004-12-13
- Assignees: Monell Chemical Senses Center
- Inventors: Liquan Huang; Jie Cao; Hong Wang; Joseph G. Brand
- Web page: https://patentgrep.com/patent/US20080307536A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides a novel splice-variant of the ClC-4 protein, termed ClC-4A. ClC-4A is expressed in taste bud cells and is involved in sour taste perception. The invention provides ClC-4A polynucleotides and ClC-4A polypeptides, vectors, host cells and ClC-4A specific antibodies as well as designing high potency taste stimuli, determining taste preferences in animals, developing breed-specific foods, and modifying the taste of foods and medications.

## Claims

### Claim 1

An isolated polynucleotide comprising a sequence selected from the group consisting of: SEQ ID NO:6, SEQ ID NO:11 and a sequence encoding a polypeptide wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:8 and variants thereof.

### Claim 2 (depends on 1)

An expression vector comprising the polynucleotide of claim 1 operably linked to a promoter.

### Claim 3 (depends on 2)

A host cell comprising the expression vector of claim 2.

### Claim 4 (depends on 3)

The host cell of claim 3 wherein said cell is a mammalian cell.

### Claim 5 (depends on 3)

The host cell of claim 3 wherein said cell is from an animal selected from the group consisting of human, mouse, rat, dog, cow, pig, cat, ox, buffalo, llama, sheep, horse, goat, llama, monkey, and ape.

### Claim 6 (depends on 3)

The host cell of claim 3 wherein said cell is from an animal selected from the group consisting of a frog, bird, bacterium, yeast, insect, and nematode.

### Claim 7 (depends on 5, 6)

A cell culture comprising at least one cell of claim 5 or 6.

### Claim 8 (depends on 1)

An isolated and purified ClC-4A polypeptide encoded by a polynucleotide of claim 1.

### Claim 9 (depends on 8)

The polypeptide of claim 8 wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:8.

### Claim 10

A method for identifying taste modifiers comprising contacting a ClC-4A polypeptide with a potential taste modifier and measuring the binding of said potential taste modifier to said ClC-4A polypeptide with respect to the binding of a natural ligand to ClC4-A.

### Claim 11 (depends on 10)

The method of claim 10 wherein said ClC-4A consists essentially of a polypeptide sequence of SEQ ID NO:8.

### Claim 12 (depends on 10)

The method of claim 10 wherein said ClC4-A polypeptide is expressed on the surface of a host cell and is encoded by a nucleic acid sequence that specifically hybridizes under stringent conditions to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:10, and SEQ ID NO:11 and wherein said polypeptide comprises as its first three amino acids the sequence Met-Leu-Leu.

### Claim 13 (depends on 10)

The method of claim 10 wherein said potential taste modifier modulates intracellular chloride concentration.

### Claim 14 (depends on 10)

The method of claim 10 wherein said host cells are Xenopus oocytes.

### Claim 15 (depends on 10)

The method of claim 10 wherein said host cells are mammalian cells.

### Claim 16 (depends on 15)

The method of claim 15 wherein said mammalian cells are selected from the group consisting of human embryonic kidney cells, Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, monkey kidney cells, N1E-115 cells, and PC 12 human hepatocellular carcinoma cells.

### Claim 17 (depends on 10)

The method of claim 10 wherein said ClC4-A polypeptides are immobilized on a solid substrate.

### Claim 18

A method for diagnosing a ClC4-A-related disease comprising contacting a test biological sample with a polynucleotide that specifically hybridizes to a nucleic acid encoding a ClC4-A polypeptide and determining the expression level of said nucleic acid, wherein a variation from expression of said nucleic acid from a known normal biological sample indicates a ClC4-A disease state.

### Claim 19 (depends on 18)

The method of claim 18 wherein said genetic analysis comprises rtPCR.

### Claim 20 (depends on 18)

The method of claim 18 wherein said genetic analysis comprises Northern hybridization.

### Claim 21 (depends on 18)

The method of claim 18 wherein said polynucleotide specifically hybridizes under stringent conditions to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:10, and SEQ ID NO:11 and wherein said polynucleotide encodes a polypeptide comprising as its first three amino acids, the sequence Met-Leu-Leu.

### Claim 22 (depends on 18)

The method of claim 18 wherein said polynucleotide comprises a sequence selected from the group consisting of: SEQ ID NO:6 and SEQ ID NO:11.

### Claim 23 (depends on 18)

The method of claim 18 wherein said polynucleotide encodes a polypeptide with the amino acid sequence of SEQ ID NO:8.

### Claim 24

A method for developing a food specific for a breed of animal comprising admixing a compound that specifically binds to a ClC-4A of said breed of animal with a dietary preparation wherein said compound is perceived as palatable by the breed of animal and is present in an amount sufficient to modify the perceived taste of said dietary preparation.

### Claim 25 (depends on 24)

The method of claim 24 wherein said compound blocks sour taste perception in said animal.

### Claim 26 (depends on 24)

The method of claim 24 wherein said compound binds to said ClC4-A with higher affinity than a natural ligand of ClC4-A.

### Claim 27 (depends on 24)

The method of claim 24 wherein said compound competes with a natural ligand for binding to ClC4-A.

### Claim 28

A dietary preparation comprising a taste modifying amount of a compound that specifically binds to a ClC4-A protein.

### Claim 29 (depends on 28)

The dietary preparation of claim 28 wherein said compound blocks sour taste perception in said animal.

### Claim 30 (depends on 28)

The dietary preparation of claim 28 wherein said compound binds to said ClC4-A with higher affinity than a natural ligand of ClC4-A.

### Claim 31 (depends on 28)

The dietary preparation of claim 28 wherein said compound competes with a natural ligand for binding to ClC4-A.

### Claim 32

A method for modulating the taste of a medication comprising adding a taste-modifying amount of a compound to said medication wherein said compound specifically binds to a ClC4-A polypeptide and is perceived as palatable by a patient to which the medicine is administered.

### Claim 33 (depends on 32)

The method of claim 32 wherein said compound blocks sour taste perception in said animal.

### Claim 34 (depends on 32)

The method of claim 32 wherein said compound binds to said ClC4-A with higher affinity than a natural ligand of ClC4-A.

### Claim 35 (depends on 32)

The method of claim 32 wherein said compound competes with a natural ligand for binding to ClC4-A.

### Claim 36

A method for enhancing the efficient use of nutrients comprising administering to an animal at least one compound that modulates ClC-4 or ClC-4A activity.

### Claim 37 (depends on 36)

The method of claim 36 wherein said compound is an agonist of ClC-4 or ClC-4A.

### Claim 38 (depends on 36)

The method of claim 36 wherein said compound is an antagonist of ClC-4 or ClC-4A.

### Claim 39 (depends on 36)

The method of claim 36 wherein one compound is an agonist of ClC-4 and wherein a second compound is an antagonist of ClC-4A.

### Claim 40 (depends on 36)

The method of claim 36 wherein one compound is an agonist of ClC-4A and wherein a second compound is an antagonist of ClC-4.

### Claim 41

A method for determining taste preference in an animal comprising determining the relative expression of ClC-4A in said animal as compared with the expression of ClC-4 wherein higher expression of ClC-4A in said animal correlates to an increased sensitivity to sour taste and a propensity to preferring foods with high potency sweeteners.

### Claim 42

A method for designing a high potency taste stimulus for ClC-4A comprising determining the binding affinity of a test compound to a ClC-4A polypeptide and modeling a second compound based on the structural features of a test compound with high affinity for ClC-4A, thereby designing a high potency taste stimulus for ClC-4A.

### Claim 43 (depends on 42)

The method of claim 42 wherein said second compound comprises a higher binding affinity for ClC-4A than said test compound.

### Claim 44

A transgenic animal comprising a polynucleotide sequence encoding a heterologous ClC-4A polypeptide.

### Claim 45

A method of making a ClC-4A transgenic animal comprising introducing into an animal a heterologous polynucleotide encoding a ClC-4A polypeptide operably linked to expression control sequences.

### Claim 46

An antibody or antigen binding portion thereof that specifically binds to a ClC-4A polypeptide.

### Claim 47 (depends on 46)

The antibody of claim 46 wherein said antibody is a monoclonal antibody.

### Claim 48 (depends on 46)

The antibody of claim 46 wherein said antigen binding portion of said antibody is selected from the group consisting of a Fab fragment, a Fab′ fragment, a F(ab)2 fragment, and a Fv fragment.

### Claim 49

A method of identifying novel agonists of ClC-4 or ClC-4A comprising comparing the primary amino acid sequence of ClC-4 or ClC-4A to other chloride channel sequences, deducing a three dimensional structure for ClC-4 or ClC-4A based on known structure of said other chloride channels, and designing molecules to fit into a ligand-binding portion of ClC-4 or ClC-4A, thereby identifying novel agonists of ClC-4 or ClC-4A.

### Claim 50 (depends on 49)

The method of claim 49 wherein the deducing step and the modeling step are computer assisted.

### Claim 51

A method of identifying novel antagonists of ClC-4 or ClC-4A comprising comparing the primary amino acid sequence of ClC-4 or ClC-4A to other chloride channel sequences, deducing a three dimensional structure for ClC-4 or ClC-4A based on known structure of said other chloride channels, and designing molecules to fit into a ligand-binding portion of ClC-4 or ClC-4A and prevent ligands from binding to the ligand binding portion of CLC-4 or ClC-4A, thereby identifying novel antagonists of ClC-4 or ClC-4A.

### Claim 52 (depends on 51)

The method of claim 51 wherein the deducing step and the modeling step are computer assisted.
